Biggest News Aggregation in the World
๐Ÿ“ฐ Laboratory Abnormalities News

Page 2 - Laboratory Abnormalities News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Laboratory Abnormalities. Real-time updates on events, politics, business and more.

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

First disclosure from Phase 3 COMMANDS study, selected for both ASCO’s official press program and EHA’s plenary session, highlights potential of Reblozyl as first-line treatment of... | May 11, 2023
United States South Korea Andrew Wei Bartl Scott Jean Marie Michot Lorettaj Nastoupil

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

11.05.2023 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the European Hematology Association (EHA) Congress, and the International Conference on Malignant ...
United States South Korea Amit Verma Saloman Manier Alit Taher Andrew Wei

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Sotyktu demonstrated superior efficacy in improving skin clearance over placebo and twice-daily Otezla® , with a well-tolerated safety profile, in the pivotal Phase 3 POETYK PSO clinical... | March 28, 2023
United States Samit Hirawat Bristol Myers Squibb Frida Dunger Johnsson Laboratory Abnormalities Amgen Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab In RELATIVITY-047, Opdualag more than
United States United Kingdom South Korea Samit Hirawat Bristol Myers Squibb European Commission

Bristol Myers Squibb Announces New Sotyktu&#x2122; (deucravacitinib) Long-Term Data Showing Clinical Effica

Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasisNew analysis to be presented at the 2022 European Academy of Dermatology and Venereology Cong...
New York United States City Of United Kingdom Jun Shen Janin Edelkamp

U.S. Food and Drug Administration Approves Sotyktu&#x2122; (deucravacitinib), Oral Treatment for Adults w

&#160;&#160;Bristol Myers Squibbโ€™s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 yearsPivotal Phase 3 POETYK PSO clinical trials demonstrate...
United States Leahm Howard April Armstrong Bristol Myers Squibb Sotyktu Samit Hirawat Bristol Myers Squibb

Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer

05.09.2022 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of scientific research across several solid tumors showcasing the breadth of the Companyโ€™s oncology development program at the European Society for Medical Oncology (ESMO) Congress ...
United States South Korea Tabitha Chan Fadi Diab David Cella Saby George

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science